Research programme: GlyT-1 selective antagonists - PfizerAlternative Names: PF-03311945
Latest Information Update: 04 Aug 2009
At a glance
- Originator Pfizer
- Mechanism of Action Glycine transporter 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 04 Aug 2009 No development reported - Preclinical for Schizophrenia in USA (unspecified route)
- 08 Dec 2005 Preclinical trials in Schizophrenia in USA (unspecified route)